Regenxbio (RGNX) Misses Q2 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regenxbio Inc. (RGNX) PT Lowered to $100 at Chardan Capital Markets, Following Drug Trial Update
August 4, 2020 2:36 PM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $100.00 (from $150.00) while maintaining a Buy rating.
... MoreRegenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
August 4, 2020 7:10 AM EDTCompany on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trialPositive interim update from Cohorts 4 and 5 at one year informs pivotal program Durable treatment effect observed with stable to improved visual acuity and retinal thickness Demonstrated meaningful reductions in anti-VEGF treatment burden over one year 61% and 85% reduction of anti-VEGF injections in Cohorts 4 and 5, respectively73% of patients (8/11) in Cohort 5 remain anti-VEGF... More
